Nan Ping Wang
Medical Practice at Columbia St, Seattle, WA
License number
Kentucky 47636
Issued Date
Sep 18, 2014
Expiration Date
Feb 29, 2016
Category
Pathology
Type
Telemedicine
Address
Address
1124 Columbia St STE 200, Seattle, WA 98104
Education
Taipei Medical University, 1985
Phone
(206) 576-6050 (Work)
Professional information
Nan Wang - Seattle, WA
Work:
Chinese Radio Seattle
Anchor/Reporter Qingdao TV station - Qingdao
journalist& news Editor Qingdao MTI international school - Qingdao
Teacher Assistant Qingdao No.2 middle school TV station - Qingdao
Editor-in-Chief
Anchor/Reporter Qingdao TV station - Qingdao
journalist& news Editor Qingdao MTI international school - Qingdao
Teacher Assistant Qingdao No.2 middle school TV station - Qingdao
Editor-in-Chief
Education:
University of Washington - Seattle, WA
BA in Communication&Economics
BA in Communication&Economics
Therapeutic Use Of The Retinoblastoma Susceptibility Gene Product
US Patent:
5851991, Dec 22, 1998
Filed:
Sep 13, 1994
Appl. No.:
8/306513
Inventors:
Wen-Hwa Lee - San Antonio TX
Eva Y-H.P. Lee - San Antonio TX
David W. Goodrich - Houston TX
H. Michael Shepard - Rancho Santa Fe CA
Nan Ping Wang - Seattle WA
Duane Johnson - Encinitas CA
Eva Y-H.P. Lee - San Antonio TX
David W. Goodrich - Houston TX
H. Michael Shepard - Rancho Santa Fe CA
Nan Ping Wang - Seattle WA
Duane Johnson - Encinitas CA
Assignee:
The Regents of the University of California - Oakland CA
Canji, Inc. - San Diego CA
Canji, Inc. - San Diego CA
International Classification:
A61K 3817
US Classification:
514 12
Abstract:
This invention provides a method of preventing or inhibiting the proliferation of a pathologically proliferating cell, wherein the pathological proliferation of the cell is the result of the absence of a functional retinoblastoma protein or polypeptide in the cell. The method requires contacting the cell with an effective amount of retinoblastoma protein or polypeptide. This method also is useful to prevent or treat retinoblastoma or a secondary cancer to retinoblastoma by administering to a patient a functional retinoblastoma protein or polypeptide.